A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia.
We carried out a double-blind and placebo-controlled study of the efficacy of bromocriptine in the treatment of nonfluent aphasia. Seven patients received bromocriptine (up to 60 mg/d) and an identical placebo in a randomized order. End points were the number of content words, content units, and pauses > 3 seconds during the description of a figure; verbal naming; and verbal fluency. There were no significant benefits of bromocriptine over placebo in any of the variables examined.
Sabe
L
L
Department of Behavioral Neurology, Raúl Carrea Institute of Neurological Research, Buenos Aires, Argentina.
Salvarezza
F
F
García Cuerva
A
A
Leiguarda
R
R
Starkstein
S
S
D000328:Adult; D000368:Aged; D001039:Aphasia, Broca / Q000188:drug therapy* / Q000523:psychology; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010919:Placebos; D013060:Speech; D016896:Treatment Outcome
D010919:Placebos; D001971:Bromocriptine